EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Differential Effects of T-Cell Inhibitors and Antimetabolites on Graft Survival in High-Risk Penetrating Keratoplasty: A Tertiary Center Experience

Susama Chokesuwattanaskul, Thanapong Somkijrungroj, Fanxiu Xiong, John A Gonzales, Vannarut Satitpitakul

Ophthalmology Science · 2026-05 · 6 (5) · 101153

DOI: 10.1016/j.xops.2026.101153 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ophthalmology Science, 2026-05. Verfasst von Susama Chokesuwattanaskul und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chulalongkorn University, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the comparative effectiveness of T-cell inhibitors versus antimetabolites on graft survival in high-risk penetrating keratoplasty (PKP), with a particular focus on cases of repeat grafting.

Design

Retrospective cohort study.

Participants

All high-risk eyes undergoing optical PKP between 2015 and 2022 at King Chulalongkorn Memorial Hospital, Bangkok, Thailand.

Methods

The medical records of 293 high-risk eyes undergoing optical PKP were reviewed. The use of any systemic steroid-sparing immunosuppressive (IS) agents was identified. In practice, all patients received either T-cell inhibitors or antimetabolites. Multivariable Cox proportional hazard models were applied to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) of the effect of systemic IS therapies on time to graft failure in high-risk PKP, adjusting for demographics, indications for PKP, and possible risk factors of graft failure. Main Outcome Measures: Time to graft failure in high-risk PKP.

Results

Among 281 high-risk eyes undergoing PKP, 217 received no IS medications, whereas 64 received IS medications (31 T-cell inhibitors, 49 antimetabolites). Notably, all eyes received topical corticosteroid immediately postoperation. In the multivariable Cox regression analysis adjusted for influential risk factors for graft failure, using any systemic IS was associated with a reduced risk of graft failure (HR: 0.71, 95% CI: 0.42-1.18), though not statistically significant. In subgroup analysis, T-cell inhibitors statistically significantly reduced the risk of graft failure (HR: 0.48, 95% CI: 0.24-0.95), whereas antimetabolites did not (HR: 0.97, 95% CI: 0.58-1.63). Among eyes with 2 or more previous grafts, IS use demonstrated a protective effect on graft failure (HR: 0.51, 95% CI: 0.28-0.94), but no benefit was observed for first-time grafts.

Conclusions

Among IS medications for high-risk PKP, T-cell inhibitors, in addition to topical corticosteroid, significantly improved graft survival, whereas antimetabolites showed no benefit. The protective effect was most pronounced in repeat transplantation, suggesting T-cell inhibitors should be preferentially considered for eyes undergoing multiple grafts. Financial Disclosures: The authors have no proprietary or commercial interest in any materials discussed in this article.

Schlagwörter

Stichwörter der Autor:innen

AntimetabolitesGraft survivalHigh-risk corneal transplantationImmunosuppressiveT-cell inhibitors

Autor:innen und Institutionen

  • Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Center of Excellence in Retina, Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Francis I. Proctor Foundation, University of California, San Francisco, San Francisco, California, USA.
  • School of Public Health, University of California, Berkeley, Berkeley, California, USA.
  • Department of Ophthalmology, University of California, San Francisco, San Francisco, California.
  • Excellence Center for Cornea and Stem Cell Transplantation, Department of Ophthalmology, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.

Förderung

  • Chulalongkorn University
  • Faculty of Medicine, Chulalongkorn University
  • King Chulalongkorn Memorial Hospital
  • University of California, San Francisco
  • National Eye Institute
  • Bristol-Myers Squibb
  • National Institutes of Health

Zitieren

APA

Chokesuwattanaskul, S., Somkijrungroj, T., Xiong, F., Gonzales, J. A., & Satitpitakul, V. (2026). Differential Effects of T-Cell Inhibitors and Antimetabolites on Graft Survival in High-Risk Penetrating Keratoplasty: A Tertiary Center Experience. Ophthalmology Science, 6(5), 101153. https://doi.org/10.1016/j.xops.2026.101153

Vancouver

Chokesuwattanaskul S, Somkijrungroj T, Xiong F, Gonzales JA, Satitpitakul V. Differential Effects of T-Cell Inhibitors and Antimetabolites on Graft Survival in High-Risk Penetrating Keratoplasty: A Tertiary Center Experience. Ophthalmology Science. 2026;6(5):101153. doi:10.1016/j.xops.2026.101153

BibTeX
@article{Chokesuwattanaskul2026,
  author = {Chokesuwattanaskul, Susama and Somkijrungroj, Thanapong and Xiong, Fanxiu and Gonzales, John A and Satitpitakul, Vannarut},
  title = {Differential Effects of T-Cell Inhibitors and Antimetabolites on Graft Survival in High-Risk Penetrating Keratoplasty: A Tertiary Center Experience},
  journal = {Ophthalmology Science},
  year = {2026},
  volume = {6},
  number = {5},
  pages = {101153},
  doi = {10.1016/j.xops.2026.101153}
}
Kostenlos starten →